On September 27, 2022, Isoray, Inc. (the Company or Isoray) entered into an Agreement and Plan of Merger (the Merger Agreement) by and among the Company, Isoray Acquisition Corp., and wholly-owned subsidiary of the Company ( Merger Sub), Viewpoint Molecular Targeting, Inc. Upon the Closing, Isoray will increase the size of its Board of Directors from 4 members to not less than 5 members. 3 of the directors will be designated by Isoray and 2 of the directors will be designated by Viewpoint. Also upon the Closing, Lori Woods will resign from her position as CEO of Isoray and Thijs Spoor will be named CEO of Isoray.
Perspective Therapeutics, Inc.
Equities
CATX
US46489V1044
Medical Equipment, Supplies & Distribution
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.495 USD | -0.99% | -5.00% | +278.11% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+278.11% | 886M | |
-5.52% | 181B | |
-0.49% | 108B | |
-6.29% | 66.57B | |
+3.05% | 49.95B | |
+6.39% | 43.84B | |
+4.91% | 41.71B | |
+21.79% | 31.59B | |
+14.45% | 25.3B | |
-6.36% | 23.94B |
- Stock Market
- Equities
- CATX Stock
- News Perspective Therapeutics, Inc.
- Isoray, Inc. Announces CEO Changes